D3 Bio reports 78% response rate for KRAS inhibitor in untreated NSCLC
June 01, 2026 | 14:15
D3 Bio announced that its KRAS G12C inhibitor elisrasib delivered a 78% objective response rate and 12.4 months median progression-free survival in first-line KRAS G12C-mutant NSCLC.
Mobile Version